Velcade, Vidaza, Vistide fall foul of Ben Venue closure
This article was originally published in Scrip
Fearing contamination, the EMA is recalling batches of Takeda's Velcade (bortezomib), Celgene's Vidaza(5-azacitidine) and Pierre Fabre's Busilvex (busulfan) manufactured at the beleaguered Ben Venu site in Ohio. The facilities are now temporarily closed while Ben Venue reviews the situation.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.